Literature DB >> 10377216

A peptide agonist acts by occupation of a monomeric G protein-coupled receptor: dual sites of covalent attachment to domains near TM1 and TM7 of the same molecule make biologically significant domain-swapped dimerization unlikely.

E M Hadac1, Z Ji, D I Pinon, R M Henne, T P Lybrand, L J Miller.   

Abstract

Membrane receptor dimerization is a well-established event for initiation of signaling at growth factor receptors and has been postulated to exist for G protein-coupled receptors, based on correction of nonfunctional truncated, mutant, or chimeric constructs by coexpression of appropriate normal complementary receptor domains. In this work, we have directly explored the molecular composition of the minimal functional unit of an agonist ligand and the wild-type G protein-coupled cholecystokinin (CCK) receptor, using photoaffinity labeling with a CCK analogue probe incorporating dual photolabile benzoylphenylalanine (Bpa) residues as sites of covalent attachment. This probe, 125I-D-Tyr-Gly-[(Nle28, 31, Bpa29,33)CCK-26-33], was shown to represent a full agonist and to specifically label the CCK receptor. Like probes incorporating individual photolabile residues in these positions,1,2 the two Bpa residues in the dual photoprobe covalently labeled receptor domains in the amino-terminal tail outside TM1 and in the third extracellular loop outside TM7. Absence of demonstrable receptor dimerization after the establishment of dual sites of covalent attachment supports the presence of these two domains within a single receptor molecule. Demonstration of the covalent adduct of a single probe molecule with the two cyanogen bromide fragments of the CCK receptor representing the expected domains further supports this interpretation. Thus, while domain-swapped dimerization of G protein-coupled receptors may be possible as a mechanism of rescue for nonfunctional molecules, it is not necessary for ligand binding and initiation of signaling at a wild-type receptor in this superfamily. The functional unit for CCK action is normally a ligand-receptor monomer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10377216     DOI: 10.1021/jm980732q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  5 in total

1.  Cell-specific targeting by heterobivalent ligands.

Authors:  Jatinder S Josan; Heather L Handl; Rajesh Sankaranarayanan; Liping Xu; Ronald M Lynch; Josef Vagner; Eugene A Mash; Victor J Hruby; Robert J Gillies
Journal:  Bioconjug Chem       Date:  2011-06-16       Impact factor: 4.774

Review 2.  Computational methods in drug design: modeling G protein-coupled receptor monomers, dimers, and oligomers.

Authors:  Patricia H Reggio
Journal:  AAPS J       Date:  2006-05-12       Impact factor: 4.009

3.  Transmembrane segment peptides can disrupt cholecystokinin receptor oligomerization without affecting receptor function.

Authors:  Kaleeckal G Harikumar; Maoqing Dong; Zhijie Cheng; Delia I Pinon; Terry P Lybrand; Laurence J Miller
Journal:  Biochemistry       Date:  2006-12-12       Impact factor: 3.162

4.  Novel benzodiazepine photoaffinity probe stereoselectively labels a site deep within the membrane-spanning domain of the cholecystokinin receptor.

Authors:  Elizabeth M Hadac; Eric S Dawson; James W Darrow; Elizabeth E Sugg; Terry P Lybrand; Laurence J Miller
Journal:  J Med Chem       Date:  2006-02-09       Impact factor: 7.446

5.  Secretin occupies a single protomer of the homodimeric secretin receptor complex: insights from photoaffinity labeling studies using dual sites of covalent attachment.

Authors:  Maoqing Dong; Polo C-H Lam; Delia I Pinon; Andrew Orry; Patrick M Sexton; Ruben Abagyan; Laurence J Miller
Journal:  J Biol Chem       Date:  2010-01-25       Impact factor: 5.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.